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Abstract
Background: Elevated production of reactive oxygen species (ROS) and an altered redox state have frequently
been observed in hepatocellular carcinoma (HCC); therefore, selective killing of HCC cells by chemotherapeutic
agents that stimulate ROS generation or impair antioxidant systems may be a feasible approach in HCC
chemotherapy. Recently, betulinic acid and its derivatives have attracted attention because they showed anti-cancer
effects via a ROS- and mitochondria-related mechanism. However, the source of ROS overproduction and the role of
mitochondria were poorly identified, and the weak in vivo antitumour activity of these compounds limits their
development as drugs.
Methods: Cytotoxicity was detected using MTT assays. In vivo anti-HCC effects were assessed using nude mice
bearing HepG2 tumour xenografts. Cell cycle analysis, apoptosis rate and mitochondrial membrane potential
were measured by flow cytometry. ROS production was detected using a microplate reader or a fluorescence
microscope. Changes in gene and protein levels were measured by RT-PCR and western blotting, respectively.
Other assays were performed using related detection kits.
Results: B5G9, a piperazidine derivative of 23-hydroxy betulinic acid (23-HBA), showed excellent in vivo anti-HCC
effects, with a tumour growth inhibitory rate of greater than 80%, and no significant side effects. B5G9 stimulated
the production of ROS, which were derived from the mitochondria, but it had no effect on various other antioxidant
systems. Moreover, B5G9 induced mitochondrial dysfunction, which was characterized by morphological changes,
membrane potential collapse, membrane permeabilization, and decreases in the O2 consumption rate and ATP
production. Furthermore, mtDNA-depleted ρ0 HepG2 cells were less sensitive to B5G9 treatment than wt HepG2 cells,
indicating the importance of mitochondria in B5G9-induced cell death.
Conclusion: We discovered a piperazidine derivative of 23-HBA, B5G9, with excellent anti-HCC effects both in vivo and
in vitro and no obvious toxic effects. The underlying mechanism was associated with mitochondria-derived ROS
overproduction, and mitochondria played essential roles in B5G9-induced cell death. This study identified a potential
agent for anti-HCC therapy and elucidated the mitochondria-related mechanism of BA and its derivatives.
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Background
Hepatocellular carcinoma (HCC), the most common
type of liver cancer, is the sixth most common malig-
nancy in the world [1]. The majority of HCC patients
are diagnosed at an advanced or even late stage due to
the unapparent initial symptoms and rapid progression.
Chemotherapy is the primary therapeutic approach
against HCC [2]. Chemotherapeutics such as sorafenib,
a tyrosine kinase inhibitor, and several other cytotoxic
drugs, are front-line anti-HCC drugs. However, these
agents are more or less toxic and have variable effects
in different patients because of the complicated mo-
lecular mechanisms of HCC, leading to decreased mor-
tality of patients [3]. Therefore, novel anti-HCC drugs
are urgently needed to improve the survival and prog-
nosis of HCC patients. Bioactive natural products or
their semi-synthetic derivatives provide an abundant
source for the development of new anti-HCC drugs due
to their low toxicity [4].
Reactive oxygen species (ROS), a by-product of the
normal metabolism of oxygen, play an important role
in cell proliferation and differentiation [5]. However,
during environmental stress, cellular ROS levels can in-
crease dramatically, which results in substantial damage
to cellular physiology and subsequent cell death [6].
Accumulating evidence has suggested that cancer cells
exhibit increased levels of ROS compared with those of
the parental cells due to oncogenic stimulation, in-
creased metabolic activity and mitochondrial dysfunc-
tion [7, 8]. Cancer cells are more sensitive to the
excessive oxidative stress induced by ROS-generating
agents or antioxidant enzyme inhibitors. Therefore, se-
lectively killing cancer cells using ROS-elevating agents
is an effective approach in cancer chemotherapy.
In normal physiological conditions, cellular ROS is
maintained at a stable level due to the dynamic balance
between ROS production and elimination. ROS over-
production or antioxidant system impairment may
result in oxidative stress [9]. Mitochondria are the pri-
mary source of endogenous ROS [10]. Under normal
conditions, 1–2% of electrons escape from the mito-
chondrial electron transport chain (ETC) and then
interact with singlet oxygen to form superoxide anions,
the initial form of ROS. However, when the ETC is dis-
turbed by environmental stimulation or mitochondria
are impaired, electrons increasingly combine with sing-
let oxygen, leading to excess ROS [11, 12]. In addition
to mitochondria, ROS are formed in the cytoplasm and
plasma membrane. NADPH oxidase, a membrane-bound
enzyme, catalyses superoxide anion production via a
1-electron reduction of molecular oxygen [13]. Other
cytoplasmic enzymes, including xanthine oxidase, cy-
clooxygenase, lipoxygenase, and cytochrome p450,
also participate in the generation of ROS via reactions
between electrons and molecular oxygen [14]. Impair-
ment of antioxidant systems, including antioxidant
enzymes and non-enzymatic ROS scavengers, may dis-
turb the balance of ROS homeostasis and trigger in-
creased ROS production. Several antioxidant inhibitors,
such as GSH inhibitors (e.g., PEITC), superoxide dismut-
ase (SOD) inhibitors (e.g., ATN-224) and Trx inhibitors
(e.g., PX-12), have shown potential antitumour activity as-
sociated with oxidative stress [15–17].
Betulinic acid (BA), a naturally occurring pentacyclic
triterpenoid isolated from white birch trees, has
attracted widespread attentions due to its multiple bio-
logical activities, such as anti-HIV, anti-cancer, anti-
malarial and anti-inflammatory effects [18, 19]. In vitro
studies have shown that BA and its analogue 23-
hydroxy betulinic acid (23-HBA) exhibited anti-cancer
activity against a wide variety of cancer cells, including
melanoma, prostate carcinoma, lung carcinoma, and
leukaemia [20–25]. To enhance the benefits and
minimize the side effects of this treatment, several
novel derivatives have been synthesized. Multiple stud-
ies have demonstrated that the antitumour mecha-
nisms of BA, 23-HBA and their derivatives may be
related to the mitochondria and ROS [26–30]. How-
ever, the underlying mechanisms are unclear, and the
source of ROS is still unknown. Thus, exploring the
mechanisms of ROS production and the relationship
between mitochondrial dysfunction and ROS produc-
tion would provide an in-depth understanding of the
antitumour mechanisms of BA, 23-HBA and their
derivatives. Recently, several in vivo antitumour exper-
iments assessing 23-HBA derivatives against H22 liver
cancer and B16 melanoma have been reported [25, 31–33],
but these derivatives showed weak antitumour activity.
Therefore, the development of novel 23-HBA deriva-
tives with excellent in vivo antitumour activity is
urgently needed.
In this study, we found that a piperazidine derivative
of 23-HBA, B5G9, exhibited excellent in vivo anti-HCC
efficiency, with a tumour growth inhibitory rate of more
than 80%, and no significant side effects in B5G9-treated
nude mice bearing HepG2 xenografts. Moreover, the
underlying mechanism of B5G9 was associated with
apoptosis induction, and we further explored the rela-
tionship among the mitochondria, ROS and apoptosis.
Methods
Reagents and antibodies
B5G9 with a purity of 98% was synthesized as described
previously [24]. Hoechst 33342, H2DCFDA, Mito-
Tracker® Red CMXRos, MitoSOX Red, a BCA protein
assay kit and a Dead Cell Apoptosis Kit were purchased
from Thermo Fisher Scientific (Waltham, MA, USA).
Necrostatin-1 was obtained from Selleck Chemicals
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(Houston, TX, USA). MnTBAP was purchased from
Santa Cruz Biotechnology (Dallas, TX, USA). An anti-
body against cytochrome c was obtained from Epitomics
(Burlingame, CA, USA). Antibodies against caspase-3,
caspase-9, cleaved-caspase-3, cleaved-caspase-9, PARP
and β-actin were obtained from Cell Signaling (Beverly,
MA, USA). Other reagents were purchased from Sigma
Aldrich (St. Louis, MO, USA).
Cell culture
The HCC cell lines HepG2 and Hep3B were obtained
from the American Type Culture Collection (ATCC,
Rockville, MD, USA). Bel-7402 cells were purchased from
the Type Culture Collection of the Chinese Academy of
Sciences (Xuhui, Shanghai, China). HepG2/ADM cells
were kindly provided by Prof. Kwok-Pui Fung (The
Chinese University of Hong Kong, Hong Kong, China).
The HepG2, Hep3B, HepG2/ADM and Bel-7402 cells
were maintained in RPMI 1640 medium (Thermo
Fisher Scientific, Waltham, MA, USA) containing 10%
(v/v) foetal bovine serum (Thermo Fisher Scientific,
Waltham, MA, USA) and 1% (v/v) penicillin-streptomycin
(PS; 10,000 U/ml, Thermo Fisher Scientific, Waltham, MA,
USA) at 37 °C in a 5% CO2 atmosphere.
Cell viability assay
HepG2, HepG2/ADM, Hep3B and Bel-7402 cells (1 ×
104/well) were seeded in 96-well plates and cultured
overnight. Then, the cells were treated with different
concentrations of B5G9 for an additional 12 h, 24 h or
36 h. Subsequently, the cells were incubated with 30 μl
of MTT (5 mg/ml) for 4 h. The formazan crystals that
formed were solubilized in 100 μl DMSO, and the ab-
sorbance was measured at 595 nm using a microplate
reader (Beckman Coulter, Brea, CA, USA). Cell viability
was calculated as a percentage of the vehicle control
(treatment with medium containing 0.2% DMSO).
Colony formation assay
HepG2 cells were seeded in 6-well microplates at a
density of 300 cells per well and cultured overnight. The
cells were then treated with various concentrations of
B5G9 for 24 h and maintained in fresh medium in an in-
cubator of 5% CO2 at 37 °C for 10 days. Next, the cells
were fixed in methanol at -20 °C for 10 min and stained
with 1% crystal violet for 20 min. Finally, the visible col-
onies were manually counted.
Tumour xenografts in nude mice
Six-week-old nude mice were obtained from Vital River
Laboratory Animal Technology Co, Ltd. (Beijing, China).
All animals were maintained in specific pathogen free
(SPF) room. The nude mice subcutaneously inoculated
with 1.5 × 107 HepG2 cells. Two weeks later, the mice
with the volume of the tumour achieved about 200 mm3
were randomly divided into four groups (seven per
group): vehicle, B5G9 (20 mg/kg and 40 mg/kg) and 23-
HBA (40 mg/kg). The drugs were administered via
intragastric injection every day. The vehicle group was
administered 0.9% NaCl. Body weight and tumour vol-
ume were measured every other day, and tumour vol-
ume was calculated as (a × b2)/2, where a and b are the
longest and the shortest diameters of the tumours,
respectively [34]. After 23 days of treatment, tumour
volume of mice in the vehicle group reached about
2000 mm3, the mice were sacrificed and the tumours,
organs and blood were collected for subsequent
measurement.
Histological examination
For histological examination, haematoxylin-eosin (H&E)
staining of the viscera was performed as described previ-
ously [35]. The images were photographed using an
Olympus IX70 inverted microscope (Olympus, Tokyo,
Japan).
Serum biochemistry and routine blood detection
After B5G9 treatment, the blood of the mice was col-
lected and serum biochemistry and routine blood ana-
lyses were carried out as described previously [36, 37].
Hoechst 33342 staining assay
HepG2 cells treated with B5G9 for 12 h were stained
with Hoechst (5 μg/ml) 33342 in the dark at 37 °C for
20 min. After being washed with phosphate-buffered sa-
line (PBS), the cells were observed using a fluorescence
microscope (Carl Zeiss, Göttingen, Germany).
Ultrastructure observation by transmission
electronic microscopy
HepG2 cells treated with B5G9 for 12 h were fixed in
3% glutaraldehyde overnight and in 1% osmium tetrox-
ide for an additional 1 h. The cells were then dehydrated
in a gradient of 50–100% ethanol and polymerized with
epoxy resin. The ultra-thin sections were stained with
aqueous uranyl acetate and lead citrate. The ultrastruc-
ture of the cells was observed using a JEM-1400 Plus
transmission electron microscope (JEOL, Tokyo, Japan).
Cell cycle analysis
HepG2 cells treated with various concentrations of
B5G9 were collected and fixed in ice-cold 70% (v/v)
ethanol at 4 °C overnight. Then, the cells were resus-
pended in PBS containing PI (10 μg/ml) and RNase
(0.1 mg/ml) and incubated at 37 °C for 30 min in the
dark. DNA content was measured with an Epics XL
Flow Cytometer (Beckman Coulter, Brea, CA, USA)
(Ex = 488 nm and Em = 620 nm).
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Annexin V-FITC/PI staining assay
HepG2 cells treated with various concentrations of
B5G9 were collected and stained with detection buffer
containing Annexin V-FITC and PI for 15 min at 37 °C
in the dark. The fluorescence was detected with an Epics
XL Flow Cytometer (Beckman Coulter, Brea, CA, USA)
(Ex = 488 nm and Em = 525 nm for Annexin V-FITC;
Ex = 488 nm and Em = 620 nm for PI).
Measurement of intracellular ROS
HepG2 cells were treated with B5G9 for the indicated
times, and the cells were stained with H2DCFDA (10 μM)
in the dark at 37 °C for 20 min. The fluorescence intensity
was observed with a fluorescence microscope or de-
tected by a microplate reader (Beckman Coulter, Brea,
CA, USA).
Lipid peroxidation detection
A Lipid Peroxidation MDA Assay Kit (Beyotime,
Shanghai, China) was used for the detection of cellular
lipid peroxidation. Methane dicarboxylic aldehyde
(MDA) was used as a characteristic product of lipid
peroxidation. In brief, cell lysates from HepG2 cells
treated with B5G9 or the MDA standards were mixed
with thiobarbituric acid (TBA) working solution ac-
cording to the manufacturer’s manual. The absorbance
at 535 nm of the MDA-TBA complex was detected with
a microplate reader (Beckman Coulter, Brea, CA, USA).
The concentration of cellular MDA was calculated ac-
cording to the standard curve.
Detection of mitochondrial membrane potential (ΔΨm)
and mitochondrial permeability transition (MPT)
For ΔΨm detection, HepG2 cells treated with B5G9 were
stained with JC-1 at 37 °C for 20 min, and the JC-1
fluorescence was detected with an Epics XL Flow Cyt-
ometer (Beckman Coulter, Brea, CA, USA). The JC-1
fluorescence conversion from red to green demonstrates
the ΔΨm collapse. For the measurement of MPT, a
mitochondrial permeability transition pore detection kit
(Genmed, Shanghai, China) was used according to the
manufacturer’s manual.
Mitochondrial morphology observation
HepG2 cells were stimulated with B5G9 for the indi-
cated times, and cells were stained with MitoTracker®
Red CMXRos at 37 °C for 30 min. Mitochondrial
morphology was observed with a fluorescence micro-
scope (Carl Zeiss, Göttingen, Germany).
Measurement of O2 consumption rate
The O2 consumption rate (OCR) was measured using an
Oxygen Consumption Rate Assay Kit (Cayman Chem-
ical, Ann Arbor, MI, USA). HepG2 cells (20,000/well)
were seeded in a 96-well plate and cultured overnight.
The cells were treated with B5G9 for the indicated times
or antimycin A for 3 h. Then, MitoXpress-Xtra was
added and HS Mineral Oil was overlaid in each well.
Finally, the MitoXpress-Xtra fluorescence was de-
tected with an Infinite F500 microplate reader
(TECAN, Männedorf, Switzerland) using time-
resolved fluorescence measurement (delay time: 30 μs;
integration time: 100 μs).
Measurement of cellular ATP
ATP content was determined using a luciferase-dependent
method. In brief, HepG2 cells seeded in 96-well plates
(20,000/well) were treated with B5G9 in complete
medium or no-glucose medium and washed with PBS
twice. Cellular ATP content was detected with a Cell
Titer-Glo 2.0 Assay kit following the manufacturer’s
protocol (Promega, Madison, WI, USA).
Generation of mtDNA-depleted ρ0 HepG2 cells
ρ0 HepG2 cells were derived from wt HepG2 cells by
maintaining the cells in EB (100 ng/ml), pyruvate
(100 μg/ml) and uridine (50 μg/ml) for more than 30
generations [38, 39]. Mitochondrial complex I, II, III, IV
and ATP synthetase activity assays (Cayman chemical,
Ann Arbor, MI, USA) and ATP measurements were
conducted to confirm the authenticity of the ρ0 HepG2
cells.
Western blotting
For total protein extraction, HepG2 cells treated with
various concentrations of B5G9 were harvested, washed
twice with ice-cold PBS and lysed in RIPA (Thermo
Fisher Scientific, Waltham, MA, USA) buffer containing
PMSF, phosphatase inhibitors and protease inhibitors for
30 min on ice. After centrifugation at 20,000 g at 4 °C
for 10 min, the supernatants were quantified using a
BCA protein assay kit. The cytoplasmic and mitochon-
drial proteins were extracted using a digitonin-based
method as described previously [40]. For western blot-
ting, proteins (50 μg per sample) were separated by
SDS-PAGE and transferred to a polyvinylidene difluoride
(PVDF) membrane (Millipore Corporation, Billerica,
MA, USA). Then, the membranes were probed with spe-
cific antibodies using standard procedures.
RT-PCR and RT2 Profiler PCR Arrays analysis
Total RNA from HepG2 cells was extracted using an
RNeasy Mini Kit (QIAGEN, Hilden, Germany). Reverse
transcription was performed using a Transcriptor First
Strand cDNA Synthesis Kit (Roche, Mannheim,
Germany) with total RNA (2 μg) as described by the
manufacturer. Then, RT-PCR was carried out by adding
SYBR Green I Master (10 μl) (Roche, Mannheim,
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Germany), forward primer (0.5 μM), reverse primer
(0.5 μM), cDNA (2 μl) and distilled water (6 μl) per
sample, and the PCR products were quantified with a
LightCycler 480 PCR system (Roche, Mannheim,
Germany). To analyse the related genes in B5G9-induced
oxidative stress, RT2 Profiler PCR Arrays (Human Oxida-
tive Stress, PAHS-065Z, QIAGEN, Hilden, Germany) were
used. Primer sequences are shown in Additional file 1:
Table S1.
Statistical analysis
Each experiment was performed for at least three times
and data are shown as the mean ± standard deviation.
Statistical analysis was performed using Graphpad Prism
4.0 by one-way ANOVA and Tukey post hoc test. A dif-
ference was considered significant when P < 0.05.
Results
In vitro and in vivo anti-HCC activities of B5G9
The in vitro anti-HCC activity of B5G9 was evaluated
using MTT assays against four HCC cell lines, HepG2,
HepG2/ADM, Hep3B and Bel-7402. As shown in
Table 1, B5G9 exhibited excellent cytotoxicity against
these four HCC cell lines, whereas 23-HBA had a weak
effect. Among the cell lines, HepG2 cells were most
sensitive to B5G9. B5G9 markedly inhibited the survival
of HepG2 cells in a dose-dependent manner (Fig. 1a).
The colony formation assay also confirmed that B5G9
inhibited the proliferation of HepG2 cells (Fig. 1b). To
determine whether B5G9 exerts anti-HCC activity in
vivo, we treated nude mice bearing HepG2 tumour xe-
nografts with vehicle, 23-HBA (40 mg/kg), B5G9
(20 mg/kg) or B5G9 (40 mg/kg) via intragastric admin-
istration once every day for 23 days. Tumour volumes
were measured every other day. As shown in Fig. 1c,
B5G9 (20 mg/kg or 40 mg/kg) had a significant inhibi-
tory effect on the growth of tumours, whereas its par-
ent compound, 23-HBA, had a minimal inhibitory
effect. At the end of the treatment, the tumours were
isolated and photographed (the photo localized in top
right corner in Fig. 1e). The tumour weights of the 20
and 40 mg/kg B5G9-treated mice were 0.34 ± 0.12 g
and 0.07 ± 0.02 g, respectively, which were significantly
lower than that of the vehicle group (0.89 ± 0.24 g)
(Fig. 1e). During the treatment period, B5G9 had no
significant effect on the body weight of the mice
(Fig. 1d) or the spleen index (Fig. 1f ), indicating that
B5G9 was well tolerated in mice. To further evaluate
the toxicity and side effects of B5G9, we collected mice
blood and organs and conducted serum biochemistry
and routine blood analyses. As indicated in Fig. 1g, rou-
tine blood indices, including measures of white blood
cells (WBCs), red blood cells (RBCs), platelets (PLTs)
and haemoglobin (HGB), exhibited no significant
changes except PLTs. The serum biochemical indices,
including creatine kinase (CK), alanine transaminase
(ALT), aspartate aminotransferase (AST) and blood
urea nitrogen (BUN), also showed no marked changes
upon B5G9 treatment (Fig. 1h). The H&E staining of
the kidney, spleen, liver and heart also showed that
B5G9 had no significant toxic effects on the major or-
gans of mice (Fig. 1i).
HepG2 cells undergo apoptotic cell death upon
B5G9 treatment
Next, we investigated the role of apoptosis in B5G9-
induced cell death. Both Hoechst 33342 staining assay
and cellular ultrastructure observation demonstrated the
apoptotic characteristics in cells treated with B5G9 (as
indicated by arrows, Fig. 2a, b). Apoptotic cell death was
further confirmed by DNA content analysis as demon-
strated by accumulation in the sub G1 phase (Fig. 2c).
Annexin-V-FITC/PI staining assays were carried out to
detect the apoptotic rate, as shown in Fig. 2d, and B5G9
induced apoptosis in a dose-dependent manner. In
addition, apoptosis-related proteins were detected by
western blot analysis. B5G9 induced the activation of
caspase-3 and caspase-9 as well as the cleavage of PARP
(Fig. 2e). Moreover, necrostatin-1, a specific inhibitor of
necroptosis, had no effect on B5G9-induced cell death
(Fig. 2f ). The above data indicated that apoptosis, but
not necroptosis, is the major process involved in B5G9-
induced cell death.
B5G9 induced apoptosis in a ROS-dependent manner
ROS, which serve as a second messenger in cellular
physiology, play an important role in apoptosis [41, 42].
To determine whether B5G9 could induce excess ROS
production in HepG2 cells, we used a fluorescence
probe, H2DCFDA. When the probe is oxidized by ROS,
it transforms into its oxidized form, DCF, which emits
bright green fluorescence. As shown in Fig. 3a and b,
DCF fluorescence significantly increased after 3 h and
further increased until 9 h after B5G9 treatment, indi-
cating that B5G9 induces oxidative stress in HepG2
cells. As a consequence of oxidative stress, cells
undergo protein oxidation, lipid peroxidation and DNA
damage [43]. Malondialdehyde (MDA), a product of
Table 1 The cytotoxicity of B5G9 in HepG2, HepG2/ADM,
Hep3B and Bel-7402 hepatoma carcinoma cell lines
Compounds IC50 (μM) (24 h)
HepG2 HepG2/ADM Hep3B Bel-7402
B5G9 3.73 ± 0.25 9.94 ± 0.50 10.00 ± 0.55 13.80 ± 0.65
23-HBA 30.35 ± 2.76 40.67 ± 3.73 39.78 ± 3.56 42.78 ± 4.03
HepG2, HepG2/ADM, Hep3B and Bel-7402 cells were treated with different
concentrations of B5G9 and 23-HBA for 24 h. Cell viability was measured by
MTT assay and IC50 values were calculated according to the MTT curves
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Fig. 1 B5G9 suppresses HepG2 cells in vitro and in vivo. a The cytotoxicity of B5G9 on HepG2 cells. HepG2 cells were treated with different
concentrations of B5G9 for 12, 24 and 36 h. Cell viability was measured by MTT assay. b The inhibitory effect of B5G9 on the colony formation of
HepG2 cells. HepG2 cells were treated with different concentrations of B5G9 for 24 h. Clonogenic survival of HepG2 cells after B5G9 treatment
was measured by the number of clones capable of anchorage-dependent growth. **P≤ 0.01 vs control. c The growth curves of HepG2 xenografts.
Nude mice bearing HepG2 xenografts were treated with B5G9 (20 or 40 mg/kg/day), 23-HBA (20 mg/kg/day) for 23 days. Tumor size was
measured every other day. ***P ≤ 0.001 vs vehicle. d The body weight curves of the mice measured every 2 days. e Tumor weights of HepG2
xenografts dissected after 23 days treatment and the photograph of the tumours isolated from nude mice. *P ≤ 0.05 vs vehicle. f B5G9 had
no effect on the spleen index. g-h B5G9 had no significant effect on routine blood indices and serum biochemistrical indices. After 23 days
treatment, the mice were killed and blood was collected. Routine blood indices (RBC, WBC, PLT, HGB) and serum biochemistrical indices
(CK, AST, ALT and BUN) were measured, **P ≤ 0.01. i B5G9 had no influence on the function of kidney, spleen, liver and heart. After 23 days
treatment, viscera were taken out for H&E staining
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lipid peroxidation, was substantially increased after
B5G9 treatment (Fig. 3c), which further confirms the
occurrence of oxidative stress. To detect the role of
ROS in B5G9-induced cell death, we pretreated HepG2
cells with N-acetyl cysteine (NAC) (an antioxidant) or
MnTBAP (a SOD mimic) before B5G9 treatment. As
shown in Fig. 3d and e, NAC or MnTBAP completely ab-
rogated B5G9-induced ROS generation and significantly
attenuated B5G9-induced cell death. These results showed
that B5G9-induced apoptotic cell death is dependent on
ROS elevation.
Identification of ROS-associated genes using a Human
Oxidative Stress Plus PCR Array
To further confirm oxidative stress induced by B5G9
and explore the mechanism of ROS burst, we used a
Fig. 2 B5G9 induces apoptotic cell death in HepG2 cells. a HepG2 cells treated B5G9 (6 μM) were stained with Hoechst 33342 (10 μg/mL) and
then observed under a fluorescence microscope. Apoptotic cells with chromatin shrinking were observed (as indicated by the arrow). Original
magnifications: × 630; scale bar: 10 μm. b The ultrastructure of HepG2 cells after B5G9 (6 μM) treatment for 24 h was observed by transmission
electron microscopy. Original magnifications: × 8900; scale bar: CTL, 5 μm; B5G9 (6 μM), 2 μm. c B5G9 triggered the accumulation of HepG2 cells
in the sub-G1 phase of the cell cycle. After B5G9 treatment, HepG2 cells were stained with PI (0.02 mg/mL). Cell cycle distribution was determined
by flow cytometry. d Apoptotic cells after B5G9 treatment were quantified by the Annexin V/PI assay. HepG2 cells treated with various concentrations
of B5G9 were stained using an Annexin V/PI kit and detected by flow cytometry. e Effects of B5G9 on the apoptosis-related proteins level. Total
cell lysate from HepG2 cells treated with B5G9 at indicated concentrations for 24 h was evaluated by western blotting, and β-actin was used
as a loading control. f B5G9-induced cell death is necrosis-independent. HepG2 cells were cultured with various concentrations of B5G9 in the
presence or absence of necrostatin-1 (50 μM) for 12 h. Cell viability was measured by the MTT assay. The results were presented as
the mean ± S.D
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Human Oxidative Stress Plus RT2 Profiler PCR Array to
identify the changes in ROS-associated gene expression
after B5G9 treatment. The results showed that five genes
(the red dots) were upregulated after B5G9 treatment
(Fig. 4a). However, the antioxidants NAC and MnTBAP
completed the abrogated B5G9-induced upregulation of
these genes (Fig. 4b-f ), whereas NAC partly enhanced
B5G9-induced HMOX1 upregulation (Fig. 4b). Thus, the
upregulation of these genes is probably a stress response
against oxidative stress. Indeed, these genes are sensitive
to oxidative stress, and some of them can mediate cellu-
lar oxidative stress [44–47]. Interestingly, we found that
only SOD2 was significantly upregulated by B5G9,
whereas SOD1 and SOD3 showed no changes (Fig. 4g).
SOD2 is a mitochondria-specific antioxidase, and its
B5G9-mediated upregulation was completely inhibited
by NAC and MnTBAP (Fig. 4g), implying that B5G9
may trigger mitochondrial oxidative stress.
Mitochondria are the major source of B5G9-induced
ROS production
Mitochondria are the main intracellular location for
oxygen consumption and energy generation, and they
are also an important source of ROS. We found that
the punctate fluorescence of H2DCFDA induced by
B5G9 (3, 6 and 9 h) can co-localize with a
mitochondria-selective probe, indicating that elevated
ROS may be produced by the mitochondria, and simi-
lar characteristics were also found in 23-HBA-treated
HepG2 cells (Fig. 5a). MitoSOX Red, a mitochondria-
targeted ROS probe, was used to further confirm these
results. As expected, B5G9 significantly increased
MitoSOX Red fluorescence from 3 to 9 h, whereas 23-
HBA had a weak effect (Fig. 5b and c). In addition to
the mitochondria, xanthine oxidase, lipoxygenase, cy-
clooxygenase, cytochrome p450 and NADPH oxidase
are sources of cellular ROS [48–51]. However, inhibi-
tors of these enzymes failed to block B5G9-induced
ROS generation (Fig. 5d). Impairment of antioxidant
enzymes, such as catalase (CAT), SOD, and glutathi-
one peroxidase (GPx), is known to induce ROS pro-
duction. However, the activities of CAT, SOD and GPx
were not inhibited (Fig. 5e). Taken together, our results
indicated that B5G9 induced mitochondrial ROS gen-
eration and had no effect on other ROS-producing
enzymes and antioxidant enzymes.
Fig. 3 B5G9-induced apoptosis is ROS-dependent. a B5G9 elevated ROS level by a time-dependent manner in HepG2 cells. HepG2 cells were
stained with H2DCFDA (10 μM) after being treated with B5G9 (6 μM) at the indicated times. The H2DCFDA fluorescence was observed by a
fluorescence microscope. Original magnifications: 100 ×; scale bar: 200 μm. b The H2DCFDA fluorescence intensity of HepG2 cells treated with
B5G9 at the indicated times was detected by a microplate reader. *P≤ 0.05, ***P≤ 0.001 vs control. c B5G9 induced lipid peroxidation. After being
treated with B5G9 (6 μM) for the indicated times, MDA level were detection by a Lipid Peroxidation MDA Assay Kit. **P≤ 0.01, ***P≤ 0.001 vs control.
d The elevated ROS level induced by B5G9 was abrogated by NAC or MnTBAP. HepG2 cells were treated with B5G9 (6 μM) in the presence or absence
of NAC (20 mM) or MnTBAP (200 μM) for 3 h. The H2DCFDA fluorescence intensity was detected by a microplate reader. *P≤ 0.05, **P≤ 0.01. e NAC or
MnTBAP alleviates B5G9-induced cell death. HepG2 cells were treated with B5G9 (6 μM) in the presence or absence of NAC (20 mM) or MnTBAP
(200 μM) for 12 h. Cell viability was measured by MTT assay. **P ≤0.01, ***P≤ 0.001
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B5G9 induces mitochondrial dysfunction
Excessive ROS production in the mitochondria leads to
mitochondrial dysfunction. Next, we investigated the
mitochondrial function following B5G9 treatment.
Morphological observation was performed with a
Mito-Tracker staining assay. As shown in Fig. 6a, in
untreated HepG2 cells, filiform mitochondria were ob-
served. By contrast, mitochondria in HepG2 cells
treated with B5G9 shrank, swelled and fragmented, in-
dicating mitochondrial dysfunction. ΔΨm collapse, a
hallmark of mitochondrial dysfunction, was induced by
B5G9 in a time-dependent manner (Fig. 6b). In
addition, B5G9 decreased the calcein-AM fluorescence,
indicating the permeabilization of the mitochondrial
membrane (Fig. 6c). This result was further confirmed
by cytochrome c translocation from the mitochondria
Fig. 4 Identification of ROS-associated genes by Human Oxidative Stress Plus PCR Array. a The gene screening of oxidative stress-related proteins.
HepG2 cells were treated with B5G9 (6 μM) for 3 h, the RT2 Profiler PCR Array was performed (left panel). The fold change values of these genes
were calculated (right panel). The changes of HMOX1 (b), SPINK1 (c), COX-2 (d) DUSP1 (e) and SOD2 (f) gene levels were consequences of ROS
overload. HepG2 cells were treated with B5G9 (6 μM) in the presence or absence of NAC (20 mM) or MnTBAP (200 μM) for 3 h, the fold changes
of these genes were detected by RT-PCR. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. g B5G9 had no effect on mRNA level of SOD1 and SOD3. HepG2 cells
were treated with B5G9 (6 μM) in the presence or absence of NAC (20 mM) for 3 h, the fold changes of these genes were detected by RT-PCR
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to the cytoplasm (Fig. 6d), which is considered a major
event of the mitochondrial apoptotic pathway. As mito-
chondria are the main location for aerobic respiration
for energy production, we next assessed the effect of
B5G9 on OCR and ATP production. As shown in
Fig. 6e, B5G9 decreased OCR in a time-dependent
manner from 3 to 9 h, and antimycin, an inhibitor of
complex III, was used as a positive control. Moreover,
the cellular ATP levels of HepG2 cells maintained in
no-glucose medium were significantly decreased upon
B5G9 treatment (Fig. 6f ), indicating that B5G9 sup-
pressed mitochondrial ATP production, because
HepG2 cells can only produce ATP by mitochondria
when glycolysis is inhibited by withdrawing glucose.
These results suggest that B5G9 induces mitochondrial
dysfunction.
Mitochondrial DNA-depleted HepG2 cells are resistant to
B5G9 treatment
To determine whether mitochondria are essential for
B5G9-induced ROS-dependent cell death, we generated
mitochondrial DNA-depleted ρ0 HepG2 cells via treat-
ment with EB, pyruvate and uridine. ATP detection and
mitochondrial complex activity assays were performed
Fig. 5 Mitochondria are the main source of B5G9-induced ROS overproduction. a B5G9-induced punctate H2DCFDA fluorescence co-localized
with mitochondrial tracker. HepG2 cells were treated with B5G9 (6 μM) or 23-HBA (30 μM) for indicated times. Then cells were stained with
H2DCFDA (10 μM) and mitotracker (100 nM) for 30 min. The fluorescence was observed by a fluorescence microscope. Original magnifications:
630 ×, scale bar: 10 μm. b-c B5G9 induced mitochondrial ROS overload. HepG2 cells were treated with B5G9 (6 μM) or 23-HBA (30 μM) for
indicated times, and then cells were stained with mitoSOX (5 μM) red for 10 min. The fluorescence was observed by a fluorescence microscope (b).
Original magnifications: 630 ×; scale bar: 10 μm. The fluorescence was also detected by a microplate reader (c), **P≤ 0.01, ***P≤ 0.001, B5G9 vs control,
##P≤ 0.01, 23-HBA vs control. d B5G9-induced elevated ROS was independent of xanthine oxidase, lipoxygenase, cyclooxygenase, cytochrome p450 or
NADPH oxidase. HepG2 cells were pretreated with allopurinol (10 μM), NDGA (10 μM), NS-398 (10 μM), SKF-525A (10 μM) or apocynin (20 μM), followed
by B5G9 (6 μM) treatment for 3 h, the H2DCFDA fluorescence intensity was detected by a microplate reader. e B5G9 had no influence on activities of
CAT, SOD and GPx. After being treated with B5G9 (6 μM) treatment for 3 h, the activities of antioxidases were measured by detection kits
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to characterize the depletion of mtDNA in ρ0 HepG2
cells. The activities of mitochondrial complex I, III and
IV, but not complex II, were significantly decreased in
ρ0 HepG2 cells (Fig. 7a). This difference occurred be-
cause all proteins of complex II are encoded by genomic
DNA, whereas other complex proteins are encoded by
genomic DNA as well as mitochondrial DNA [52]. As a
result of mitochondrial complex subunit depletion, ATP
levels in HepG2 cells treated with 2-deoxyglucose (2-
DG), an inhibitor of glycolysis, significantly decreased
(Fig. 7b) due to the impairment of ATPase activity
(Fig. 7c), but in the absence of 2-DG, ATP levels showed
no significant difference between wt and ρ0 HepG2 cells
because ρ0 HepG2 cells can use glycolysis to survive in
Fig. 6 B5G9 treatment induces mitochondrial dysfunction. a B5G9 induced mitochondrial morphology changes. HepG2 cells treated with B5G9
(6 μM) for indicated times were stained with MitoTracker Red CMXRos (100 nM) for 20 min, the cells were observed by a fluorescence
microscope. Original magnifications: 630 ×; scale bar: 10 μm, (b) B5G9 induced mitochondrial membrane potential collapse. HepG2 cells were
treated with B5G9 (6 μM) for indicated times, and then stained with JC-1 (5 μM) fluorescence dye, and changes of ΔΨm were determined by flow
cytometry. c B5G9 increased mitochondrial membrane permeabilization. HepG2 cells were treated with B5G9 (6 μM) for indicated times, then
cells were incubated with calcein-AM for 30 min, the fluorescence was detected by a microplate reader, *P≤ 0.05, **P ≤ 0.01 vs control. d Cyto
c released from mitochondria to cytoplasm after B5G9 treatment. After being treated with various concentrations of B5G9 for 24 h, HepG2 cells
lysate was divided into mitochondrial fraction and cytoplasmic fraction and detected by western bolt, β-actin and VDAC were used as loading
controls for cytoplasm and mitochondria respectively. e O2 consumption rate was inhibited by B5G9. HepG2 cells were treated with B5G9 (6 μM)
for 3, 6, 9 h and antimycin (6 μM) for 3 h, the O2 consumption rate was measured by a MitoXpress-Xtra-based assay. **P≤ 0.01, ***P≤ 0.001 vs control.
f B5G9 impaired mitochondrial ATP production. HepG2 cells were treated with B5G9 (6 μM) for 3, 6 and 9 h in complete medium or no-glucose
medium, the ATP level was detected by a CellTiter-Glo Luminescent Assay, **P≤ 0.01, ***P≤ 0.001
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the presence of pyruvate and uridine. Moreover, Mito-
SOX Red fluorescence was markedly elevated in wt
HepG2 cells treated with B5G9, whereas the fluores-
cence in ρ0 HepG2 cells only slightly increased (Fig. 7d),
which further indicated that B5G9-induced ROS gener-
ation was derived from mitochondria. The sensitivity of
wt and ρ0 HepG2 cells to B5G9 treatment was measured
with MTT assays. As expected, ρ0 HepG2 cells were re-
sistant to B5G9 (Fig. 7e), indicating that mitochondria
play an important role in B5G9-induced ROS-dependent
cell death.
Discussion
Traditional Chinese medicine (TCM) is an abundant
source of anti-HCC agents. Recently, the modification
of natural products from TCM has become a promising
approach for novel drug development. To enhance the
antitumour efficacy of 23-HBA and reduce its side ef-
fects, we performed a series of structural modifications
of 23-HBA and conducted a bioactivity screening [24].
We found that a piperazidine derivative of 23-HBA,
B5G9, showed excellent anti-HCC activity both in vitro
and in vivo.
In the current study, we evaluated the anti-HCC activ-
ity of B5G9 on four HCC cell lines, including HepG2,
Bel-7402 and Hep3B cells (p53-null), and multidrug-
resistant HepG2/ADM cells. B5G9 showed comparable
cytotoxicity in the four hepatoma cell lines, which indi-
cates the potential of B5G9 in the treatment of various
types of HCC cells, regardless of p53 status. B5G9 also ex-
hibited outstanding anti-proliferation activity on HepG2
tumour xenografts without significant toxicity, whereas
23-HBA had a minimal effect.
ROS generation is considered the key mechanism for
the anti-cancer activity of BA and 23-HBA [27, 28, 53].
However, the source of ROS was unclear. In the Human
Oxidative Stress Plus PCR Array, we surprisingly found
that B5G9-induced mitochondria-specific SOD2 upregu-
lation was completely inhibited by antioxidants. The re-
sults indicated that the mitochondria might undergo
oxidative stress. This hypothesis was confirmed by the
co-localization of H2DCFDA and Mito-Tracker as well
as MitoSOX Red staining. We found that 23-HBA had a
Fig. 7 ρ0 HepG2 cells were less sensitive to B5G9 treatment. a Mitochondrial complex activities of wt HepG2 or ρ0 HepG2 were detected by
related assay kits, ***P ≤ 0.001. b ATP production of ρ0 HepG2 cells was significantly decreased in the present of 2-DG. After being treated with
2-DG (2 mM) for 2 h, ATP level of wt HepG2 or ρ0 HepG2 was measured by a CellTiter-Glo Luminescent Assay, ***P ≤ 0.001. c ρ0 HepG2 had a
lower ATP synthetase activity than wt HepG2. The ATP synthetase activity of wt HepG2 treated in the present or absent of oligomycin (6 μM) and
ρ0 HepG2 was measured by a cayman ATP synthetase activity kit, **P≤ 0.01. d ρ0 HepG2 cells had no significant change in mitoSOX red fluorescence
after B5G9 treatment, original magnifications : 630 ×; scale bar: 10 μm. e ρ0 HepG2 cells were less sensitive to B5G9 treatment. Being treated
with various concentrations of B5G9 for 12 h, cell viability was measured by MTT assay. *P ≤ 0.01, ***P ≤ 0.001
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similar but weaker effect, which could explain why B5G9
had greater anti-HCC activity than that of 23-HBA; how-
ever, B5G9 may have a different underlying mechanism of
mitochondrial dysfunction. Moreover, we noted that
B5G9 just induced a slight increase of mitochondrial ROS
and apoptosis in normal liver LO2 cells compare to
HepG2 cells (Additional file 2: Figure S1A&B) which indi-
cated its selective cytotoxicity against HCC cells. These re-
sults also implied the important role of mitochondrial
ROS in B5G9-induced apoptosis. In addition to mitochon-
dria, NADPH oxidase, XO, LOX, COX and cytochrome
p450 contribute to ROS overproduction, but the results
showed that inhibitors of these enzymes failed to abolish
B5G9-induced ROS production. All these data indicate
that mitochondria are the major site of B5G9-induced
ROS production. Inhibition of mitochondrial complex ac-
tivity (especially complex I and III) can induce ROS pro-
duction [54, 55]. We further measured mitochondrial
complex activities upon B5G9 treatment by cell-based
assay. As shown in Additional file 2: Figure S1C, B5G9
treatment (0.5, 1 and 3 h) had no effect on activities of
mitochondrial complex I, III and V. In our study, B5G9-
induced mitochondrial-ROS burst was observed at 3 h.
These data indicate that B5G9-induced mitochondrial-
ROS overload was probably not a result of mitochondrial
complex complex inhibition. The mechanisms underlying
B5G9-induced mitochondrial-ROS burst are complicated
and need be explored in our future study. Recently, BA
was found to induce ROS production in hepatocellular
carcinoma via a p53-dependent p66shc/miR-21-Sod2 path-
way [53]. However, B5G9 could also induce oxidative
stress in Hep3B cells (Additional file 2: Figure S1D), indi-
cating that a p53-independent mechanism underlying the
ROS burst induced by B5G9 must exist. Wolfgang Wick
found that BA-induced ROS generation required new pro-
tein synthesis [27], but this was not observed in our stud-
ies because cycloheximide (CHX), an inhibitor of de novo
protein synthesis, could not inhibit the ROS induced by
B5G9 (Additional file 2: Figure S1E&F). This result was
also confirmed by the fact that five genes (HMOX1,
SPINK1, COX-2, DUSP1 and SOD2) were significantly
upregulated by B5G9, and their upregulation was a conse-
quence of ROS production (Fig. 4). Dual-specificity phos-
phatase 1 (DUSP1) is a negative regulator of MAPKs that
dephosphorylates both the threonine/serine and tyrosine
residues of the substrates to facilitate tumourigenesis [56].
In human HCC, the activated RAS-MAPK cascade leads
to ERK activation, which results in the phosphorylation of
its inhibitor, DUSP1. Then, the phosphorylated DUSP1 is
degraded by the ubiquitin proteasome system [57]. Hence,
DUSP1 is negatively correlated with ERK activity and acts
as a negative regulator of HCC development [58]. Thus,
DUSP1 upregulation may be a promising approach in
HCC therapy. In our study, we found that the DUSP1
mRNA level was substantially upregulated; however, the
role of DUSP1 in B5G9-induced HepG2 cell death re-
quires further study.
It has been frequently reported that BA as well as its
derivatives activated the mitochondrial apoptotic pathway.
Unfortunately, few studies have examined the requirement
of mitochondria for their anti-cancer effects. To gain
insight into this issue, we established a mitochondrial
DNA-depleted ρ0 HepG2 cell line. B5G9 only slightly in-
creased the fluorescence of MitoSOX Red in ρ0 HepG2
cells, and ρ0 HepG2 cells were less sensitive to the B5G9
treatment compared with wt HepG2 cells. These phenom-
ena are partly due to the incomplete efficiency of mito-
chondrial DNA depletion. Nevertheless, these results
indicate that mitochondria play a crucial role in B5G9-
induced cell death. MPT is a key event in the mitochon-
drial apoptotic pathway. BA-induced MPT was a conse-
quence of the opening of the mitochondrial PT pore,
which was abolished by cyclosporine A (CsA) or bongk-
rekic acid [59, 60]. In contrast to these data, we found that
cyclosporine failed to alleviate B5G9-induced MPT and
cell death (Additional file 2: Figure S1G&H). Recently, a
novel mechanism associated with mitochondrial cardioli-
pin was discovered. BA induced cancer cell death by
modifying the biosynthesis of cardiolipin . This modifica-
tion was accomplished by the inhibition of the activity of
steroyl-CoA-desaturase [61]. Moreover, BA could also in-
duce MPT by directly interacting with the mitochondrial
membrane to change the permeability of the cardiolipin
film [62]. These results suggested that piperazidine may
enhance the mitochondrial cardiolipin modification effect,
and this should be further investigated.
Conclusion
In summary, we discovered a piperazidine derivative of 23-
HBA, B5G9, with excellent anti-HCC effects both in vivo
and in vitro, and no obvious toxic effects. The underlying
mechanism was associated with mitochondria-derived ROS
production, and we further identified the importance of the
mitochondria in B5G9-induced cell death. This study iden-
tifies a potential agent for anti-HCC therapy and elucidates
the source of ROS induced by BA and its derivatives.
Additional files
Additional file 1: Table S1. Primer sequences of oxidative stress-related
genes. (DOCX 16 kb)
Additional file 2: Figure S1. (A) Effect of B5G9 on mitochondrial-ROS
production of LO2 cells. HepG2 and LO2 cells were treated with B5G9
(6 μM) for indicated times, and then cells were stained with mitoSOX
(5 μM) red for 10 min. The fluorescence was detected by a microplate
reader, ***P ≤ 0.001, B5G9 vs control (HepG2). (B) Effect of B5G9 on cell
apoptosis of LO2 or HepG2 cells. HepG2 or LO2 cells were treated with
B5G9 (6 and 8 μM) for 24 h. Apoptotic rate (PI positive cells plus Annexin
V positive cells) was measured by PI/Annexin V assay. **P ≤0.01. (C) B5G9
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had no effect on mitochondrial complex I, III and V activities. Mitochondrial
protein of HepG2 cells treated with B5G9 (6 μM) for 0.5, 1 and 3 h were
extracted, and then activities of mitochondrial complex I, III and V were
detected using related detection kit. *P≤ 0.05, **P≤ 0.01 vs control. (D) B5G9
induced ROS overload in Hep3B cells in a time-dependent manner. Hep3B
cells were stained with H2DCFDA (10 μM) after being treated with B5G9
(6 μM) for indicated times. The fluorescence of H2DCFDA was measured by
a microplate reader. ***P≤ 0.001 vs control. (E) B5G9 induced ROS overload
was protein de novo synthesis independent. HepG2 cells were exposed with
B5G9 (6 μM) for 6 h after pretreatment with CHX (10 μM). The fluorescence
of H2DCFDA was observed by a fluorescence microscope and measured by
a microplate reader (F). Original magnifications: 200 ×; scale bar: 50 μm. (G)
B5G9 induced mitochondrial membrane permeabilization was PT pore-
independent. HepG2 cells were treated with B5G9 (6 μM) in the presence or
absence of CsA (5 μM) for 6 h, then cells were incubated with calcein-AM
for 30 min, the fluorescence was detected by a microplate reader. (H) CsA
could not rescue B5G9 induced cell death in HepG2 cells. HepG2 cells were
treated with B5G9 in the presence or absence of CsA (5 μM) for 12 h, cell
viability was detected by MTT assay. (TIF 2973 kb)
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